Bacteriophage Therapy in Tonsillitis (NCT04682964) | Clinical Trial Compass
Active — Not RecruitingPhase 3
Bacteriophage Therapy in Tonsillitis
Uzbekistan128 participantsStarted 2020-10-02
Plain-language summary
The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa. A total of 5 ml of PCL was inhaled for 10 minutes every 5 days. The drug causes the lysis of certain bacteria, including staphylococcus, enterococcus, streptococcus, enteropathogenic E. coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Klebsiella oxytoca. The choice of this drug was based on bacteriological studies.
Who can participate
Age range
3 Years – 14 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* children from 3 to 14 years old.
* children with sore throat.
* children diagnosed with acute tonsillitis.
* children diagnosed with acute respiratory infection (rhinitis, sinusitis, nasopharyngitis).
* children with the opportunity to visit the outpatient clinic.
* children with the ability to receive inhalation therapy.
* children from parents (or guardians) who have given written permission to conduct clinical and laboratory research.
Exclusion Criteria:
* children under 3 years old and over 14 years old.
* children receiving hospital treatment.
* children with acute respiratory tract diseases (bronchitis, pneumonia, pleurisy).
* children with сhronic respiratory tract diseases (bronchitis, pneumonia).
* children who are allergic to antibiotics.
* children with cancer, immunological and hematological diseases.
* children with severe psychological illnesses (schizophrenia, mental retardation, etc.)
* children with cancer, immunological and hematological diseases.
* children with tuberculosis.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.